Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;16(1):153-159.
doi: 10.25122/jml-2022-0172.

Features of VEGF and IL-6 expression in patients with inflammatory breast cancer considering molecular-biological characteristics

Ivan Ivanovich Smolanka  1 , Irina Yuriivna Bagmut  2 , Oleksii Volodimirovich Movchan  1 , Michael Ivanovich Sheremet  3 , Oleksandr Mykolayovych Bilyi  4 , Andriy Oleksandrovich Lyashenko  1 , Irina Viktorivna Dosenko  1 , Anton Dmitrovich Loboda  1 , Oksana Mykolaivna Ivankova  1 , Igor Leonidovich Kolisnyk  2
Affiliations

Features of VEGF and IL-6 expression in patients with inflammatory breast cancer considering molecular-biological characteristics

Ivan Ivanovich Smolanka et al. J Med Life. 2023 Jan.

Abstract

Expression of pro-malignant factors (VEGF) and cytokines like inflammatory components support breast cancer development. We examined 46 patients with stage IIIB inflammatory breast cancer (IBC) and 24 with stage IIA-IIIB breast cancer (BC) without secondary edema. Hormone receptors, Her-2/neu, Ki-67 index, VEGF, and IL-6, were determined for all patients before and after neoadjuvant treatment. They associated the expression of VEGF for IBC patients with an unfavorable prognosis. VEGF level for IBC lymph node metastases was higher than in patients without such lesions (1.4 times), and there was a significant increase in VEGF levels in the G3 category of malignancy (1.54-fold increase). In IBC patients with positive HER2/neu status, VEGF levels were 1.51 times higher compared to those with negative HER2/neu status (r=0.36, p<0.05). IL-6 level during therapy in IBC patients remained high, which occurs in active tumor development. Comparative analysis of the VEGF/IL-6 ratio during treatment of patients with IBC was higher vs. IIIB stage breast cancer without edema (1.4 vs. 0.7), indicating the aggressiveness of the tumor process and confirmed by an objective response to treatment (regression<30%).

Keywords: inflammatory breast cancer; interleukin-6; neoadjuvant chemotherapy personalization; vascular endothelial growth factor.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Menopause status and VEGR correlation.
Figure 2
Figure 2
Menopause status and IL-6 correlation.
Figure 3
Figure 3
VEGF dynamics before and after chemotherapy.
Figure 4
Figure 4
IL-6 dynamics before and after chemotherapy.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel R, et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA CANCER J CLIN. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Cardoso F, Senkus E, Costa A, Papadopoulos E, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol. 2018;29(8):1634–1657. doi: 10.1093/annonc/mdy192. - DOI - PMC - PubMed
    1. Goldberg J, Schwertfeger K. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets. 2010;11(9):1133–1146. doi: 10.2174/138945010792006799. 2010 Sep; 11(9):1133-46. - DOI - PubMed
    1. Tirada N, Aujero M, Khorjekar G, Richards S, et al. Breast Cancer Tissue Markers, Genomic Profiling, and Other Prognostic Factors: A Primer for Radiologists. Radiographics. 2018;38(7):1902–1920. doi: 10.1148/rg.2018180047. - DOI - PubMed
    1. Zhao H, Wu L, Yan G, Chen Y, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Sig Transduct Target Ther. 2021;6:263–270. doi: 10.1038/s41392-021-00658-5. - DOI - PMC - PubMed